Brief: Sandoz Group Reaches Agreement With Regeneron, Resolving Patent Litigation Related To Its U.S. Aflibercept Biosimilar

Sandoz AG

09/09/2025 06:07

Sept 9 (Reuters) - Sandoz Group AG SDZ.S:

SANDOZ REACHES AGREEMENT WITH REGENERON, RESOLVING ALL PATENT LITIGATION RELATED TO ITS US AFLIBERCEPT BIOSIMILAR

ENZEEVU™ LAUNCH EXPECTED BY END OF 2026

SANDOZ MAY ENTER US MARKET WITH A BIOSIMILAR VERSION OF EYLEA^® IN Q4 OF 2026, OR EARLIER IN CERTAIN CIRCUMSTANCES

Source text: ID:nEQ6Q9M84a

Further company coverage: SDZ.S

 (Gdansk Newsroom)

 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))